We have 6 of 34 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Not available.
Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...
The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.
The data support recent recommendations advising treating patients with tandem transplantation regimes and support the idea that the optimal consolidation strategy remains to be defined.
These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
